Rhenman & Partners Asset Management AB
Latest statistics and disclosures from Rhenman & Partners Asset Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BSX, REGN, LLY, INSM, CVS, and represent 19.46% of Rhenman & Partners Asset Management AB's stock portfolio.
- Added to shares of these 10 stocks: SYK (+$16M), VEEV (+$15M), BSX (+$12M), ABT (+$12M), WAY (+$8.3M), INSM (+$7.6M), APGE (+$6.3M), GH (+$6.0M), GILD (+$5.8M), CAH (+$5.7M).
- Started 11 new stock positions in ESPR, CMPX, APGE, VEEV, ABT, NVCR, NKTR, SYK, CAH, WAY. SION.
- Reduced shares in these 10 stocks: VERA (-$21M), COO (-$20M), MDT (-$18M), ALGN (-$16M), DHR (-$15M), GKOS (-$14M), REGN (-$10M), PODD (-$9.9M), PEN (-$9.8M), APLS (-$9.4M).
- Sold out of its positions in APLS, ACLX, BNTX, BRKR, CNC, CNTA, CYTK, IRTC, INSP, JANX. PEN, PRVA, RDNT, RYTM, TGTX, VERA, WST, XNCR, QURE.
- Rhenman & Partners Asset Management AB was a net seller of stock by $-187M.
- Rhenman & Partners Asset Management AB has $811M in assets under management (AUM), dropping by -24.25%.
- Central Index Key (CIK): 0001599882
Tip: Access up to 7 years of quarterly data
Positions held by Rhenman & Partners Asset Management AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 86 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation (BSX) | 4.8 | $39M | +44% | 625k | 62.75 |
|
| Regeneron Pharmaceuticals (REGN) | 4.6 | $37M | -21% | 48k | 772.64 |
|
| Eli Lilly & Co. (LLY) | 3.8 | $31M | -20% | 34k | 919.77 |
|
| Insmed Com Par $.01 (INSM) | 3.2 | $26M | +40% | 160k | 163.52 |
|
| CVS Caremark Corporation (CVS) | 3.0 | $24M | 337k | 71.82 |
|
|
| Gilead Sciences (GILD) | 2.9 | $23M | +32% | 168k | 139.37 |
|
| Thermo Fisher Scientific (TMO) | 2.5 | $20M | +22% | 41k | 491.53 |
|
| Biogen Idec (BIIB) | 2.5 | $20M | +18% | 109k | 183.33 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.4 | $19M | +26% | 44k | 446.54 |
|
| Alignment Healthcare (ALHC) | 2.3 | $19M | +4% | 1.1M | 17.62 |
|
| Intuitive Surgical Com New (ISRG) | 2.1 | $17M | -23% | 37k | 460.99 |
|
| AmerisourceBergen (COR) | 2.0 | $17M | -17% | 52k | 314.14 |
|
| Stryker Corporation (SYK) | 1.9 | $16M | NEW | 48k | 328.59 |
|
| Abbvie (ABBV) | 1.9 | $16M | -35% | 72k | 217.49 |
|
| Veeva Sys Cl A Com (VEEV) | 1.8 | $15M | NEW | 85k | 175.66 |
|
| McKesson Corporation (MCK) | 1.8 | $15M | -34% | 17k | 865.36 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 1.8 | $14M | +2% | 76k | 189.05 |
|
| Guardant Health (GH) | 1.7 | $13M | +81% | 145k | 92.37 |
|
| Neurocrine Biosciences (NBIX) | 1.6 | $13M | -19% | 101k | 131.74 |
|
| Edwards Lifesciences (EW) | 1.6 | $13M | -15% | 163k | 80.08 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.6 | $13M | +23% | 24k | 523.47 |
|
| UnitedHealth (UNH) | 1.5 | $12M | -17% | 46k | 270.59 |
|
| Procept Biorobotics Corp (PRCT) | 1.5 | $12M | -22% | 475k | 25.01 |
|
| BioMarin Pharmaceutical (BMRN) | 1.4 | $12M | -3% | 207k | 56.49 |
|
| Abbott Laboratories (ABT) | 1.4 | $12M | NEW | 112k | 102.67 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.4 | $11M | -24% | 35k | 330.87 |
|
| Royalty Pharma Shs Class A (RPRX) | 1.4 | $11M | +12% | 233k | 47.97 |
|
| Axsome Therapeutics (AXSM) | 1.3 | $11M | -44% | 64k | 169.02 |
|
| Natera (NTRA) | 1.3 | $10M | +27% | 52k | 199.99 |
|
| Tenet Healthcare Corp Com New (THC) | 1.3 | $10M | -29% | 54k | 188.71 |
|
| Adaptive Biotechnologies Cor (ADPT) | 1.2 | $10M | +19% | 720k | 13.88 |
|
| Livanova SHS (LIVN) | 1.2 | $9.9M | -18% | 155k | 63.56 |
|
| Anthem (ELV) | 1.2 | $9.5M | +115% | 32k | 292.75 |
|
| Arrowhead Pharmaceuticals (ARWR) | 1.1 | $9.1M | 145k | 62.70 |
|
|
| Glaukos (GKOS) | 1.1 | $9.0M | -60% | 84k | 107.66 |
|
| Iqvia Holdings (IQV) | 1.1 | $9.0M | +100% | 53k | 170.54 |
|
| Syndax Pharmaceuticals (SNDX) | 1.1 | $8.9M | -22% | 379k | 23.36 |
|
| Mirum Pharmaceuticals (MIRM) | 1.1 | $8.6M | -12% | 93k | 92.38 |
|
| Ideaya Biosciences (IDYA) | 1.1 | $8.5M | +2% | 256k | 33.32 |
|
| Pennant Group (PNTG) | 1.0 | $8.4M | -22% | 275k | 30.48 |
|
| Nuvalent Inc-a (NUVL) | 1.0 | $8.3M | -50% | 81k | 102.45 |
|
| Waystar Holding Corp (WAY) | 1.0 | $8.3M | NEW | 343k | 24.11 |
|
| Anteris Technologies Global (AVR) | 1.0 | $8.0M | +16% | 1.4M | 5.55 |
|
| Medtronic SHS (MDT) | 1.0 | $7.8M | -69% | 90k | 86.65 |
|
| Oscar Health Cl A (OSCR) | 0.9 | $7.6M | +153% | 660k | 11.47 |
|
| Iovance Biotherapeutics (IOVA) | 0.9 | $7.2M | +28% | 2.1M | 3.51 |
|
| Mineralys Therapeutics (MLYS) | 0.9 | $7.1M | +84% | 263k | 27.09 |
|
| Ionis Pharmaceuticals (IONS) | 0.9 | $7.0M | -41% | 93k | 75.09 |
|
| Dianthus Therapeutics (DNTH) | 0.8 | $6.9M | -17% | 82k | 83.92 |
|
| Bridgebio Pharma (BBIO) | 0.8 | $6.7M | +11% | 91k | 74.26 |
|
| Apogee Therapeutics (APGE) | 0.8 | $6.3M | NEW | 75k | 84.17 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.8 | $6.2M | -13% | 128k | 48.20 |
|
| Cardinal Health (CAH) | 0.7 | $5.7M | NEW | 27k | 211.31 |
|
| Encompass Health Corp (EHC) | 0.7 | $5.4M | -61% | 56k | 96.73 |
|
| Amgen (AMGN) | 0.7 | $5.3M | -57% | 15k | 351.85 |
|
| Viking Therapeutics (VKTX) | 0.6 | $5.2M | +92% | 160k | 32.54 |
|
| Nurix Therapeutics (NRIX) | 0.6 | $4.9M | -41% | 314k | 15.50 |
|
| Alkermes SHS (ALKS) | 0.6 | $4.7M | 133k | 35.36 |
|
|
| Charles River Laboratories (CRL) | 0.6 | $4.5M | +18% | 26k | 172.50 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.6 | $4.5M | -34% | 240k | 18.64 |
|
| Krystal Biotech (KRYS) | 0.5 | $4.3M | -33% | 17k | 258.32 |
|
| Doximity Cl A (DOCS) | 0.5 | $4.3M | -50% | 184k | 23.30 |
|
| Nektar Therapeutics Com New (NKTR) | 0.5 | $4.2M | NEW | 59k | 71.95 |
|
| Denali Therapeutics (DNLI) | 0.5 | $3.8M | +99% | 199k | 19.20 |
|
| Stevanato Group S P A Ord Srs (STVN) | 0.5 | $3.8M | +86% | 275k | 13.75 |
|
| Relay Therapeutics (RLAY) | 0.4 | $3.6M | -21% | 360k | 9.95 |
|
| Cooper Cos (COO) | 0.4 | $3.6M | -84% | 50k | 71.50 |
|
| Sionna Therapeutics (SION) | 0.4 | $3.5M | NEW | 88k | 40.09 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.4 | $3.4M | 15k | 228.73 |
|
|
| Danaher Corporation (DHR) | 0.4 | $3.4M | -81% | 18k | 189.60 |
|
| Insulet Corporation (PODD) | 0.4 | $2.9M | -77% | 14k | 209.84 |
|
| Agilent Technologies Inc C ommon (A) | 0.4 | $2.8M | +25% | 25k | 113.98 |
|
| Stoke Therapeutics (STOK) | 0.3 | $2.7M | -61% | 83k | 32.56 |
|
| Esperion Therapeutics (ESPR) | 0.3 | $2.7M | NEW | 985k | 2.74 |
|
| Immunocore Hldgs Ads (IMCR) | 0.3 | $2.6M | -44% | 86k | 30.15 |
|
| Ocular Therapeutix (OCUL) | 0.3 | $2.6M | +15% | 305k | 8.47 |
|
| Steris Shs Usd (STE) | 0.3 | $2.5M | +91% | 12k | 221.13 |
|
| Vericel (VCEL) | 0.3 | $2.3M | -40% | 70k | 32.17 |
|
| Kura Oncology (KURA) | 0.3 | $2.2M | -68% | 272k | 8.13 |
|
| Cigna Corp (CI) | 0.3 | $2.1M | -79% | 8.0k | 266.75 |
|
| Brightspring Health Svcs (BTSG) | 0.3 | $2.1M | -74% | 50k | 42.61 |
|
| Xenon Pharmaceuticals (XENE) | 0.2 | $1.6M | -79% | 28k | 58.15 |
|
| Align Technology (ALGN) | 0.2 | $1.3M | -92% | 7.5k | 171.43 |
|
| Novocure Ord Shs (NVCR) | 0.1 | $763k | NEW | 70k | 10.90 |
|
| Alphatec Hldgs Com New (ATEC) | 0.1 | $762k | +250% | 70k | 10.88 |
|
| Compass Therapeutics (CMPX) | 0.1 | $609k | NEW | 115k | 5.29 |
|
Past Filings by Rhenman & Partners Asset Management AB
SEC 13F filings are viewable for Rhenman & Partners Asset Management AB going back to 2013
- Rhenman & Partners Asset Management AB 2026 Q1 filed May 14, 2026
- Rhenman & Partners Asset Management AB 2025 Q4 filed Feb. 13, 2026
- Rhenman & Partners Asset Management AB 2025 Q3 filed Nov. 13, 2025
- Rhenman & Partners Asset Management AB 2025 Q2 filed Aug. 13, 2025
- Rhenman & Partners Asset Management AB 2025 Q1 filed May 14, 2025
- Rhenman & Partners Asset Management AB 2024 Q4 filed Feb. 13, 2025
- Rhenman & Partners Asset Management AB 2024 Q3 filed Nov. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q2 filed Aug. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q1 filed May 14, 2024
- Rhenman & Partners Asset Management AB 2023 Q3 restated filed Nov. 13, 2023
- Rhenman & Partners Asset Management AB 2023 Q3 filed Nov. 9, 2023
- Rhenman & Partners Asset Management AB 2023 Q2 filed Aug. 11, 2023
- Rhenman & Partners Asset Management AB 2023 Q1 filed May 12, 2023
- Rhenman & Partners Asset Management AB 2022 Q4 filed Feb. 13, 2023
- Rhenman & Partners Asset Management AB 2022 Q3 filed Nov. 14, 2022
- Rhenman & Partners Asset Management AB 2022 Q2 filed Aug. 12, 2022